Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics ...

Fintel reports that on November 18, 2024, D. Boral Capital initiated coverage of Lineage Cell Therapeutics (NYSEAM:LCTX) with a Buy recommendation. Analyst Price Forecast Suggests 478.36% Upside ...

U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion.Capstan develops CAR-T therapies, a type of treatment that uses ...

The projected annual revenue for Lineage Cell Therapeutics is 14MM, an increase of 65.83%. ... Logos Global Management holds 5,000K shares representing 2.65% ownership of the company.